尚荣医疗
(002551)
| 流通市值：18.62亿 | | | 总市值：25.77亿 |
| 流通股本：6.10亿 | | | 总股本：8.45亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,002,639,030.84 | 631,461,882.24 | 276,144,984.63 | 1,192,887,048.61 |
| 营业收入 | 1,002,639,030.84 | 631,461,882.24 | 276,144,984.63 | 1,192,887,048.61 |
| 二、营业总成本 | 990,946,064.65 | 625,939,925.56 | 268,848,379.08 | 1,211,329,549.79 |
| 营业成本 | 843,830,113.81 | 535,000,227.83 | 226,996,833.33 | 995,282,795.69 |
| 税金及附加 | 15,273,208.2 | 9,912,287.05 | 4,470,962.37 | 20,138,186.58 |
| 销售费用 | 11,448,990.8 | 7,397,845.43 | 3,108,322.17 | 24,098,710.15 |
| 管理费用 | 107,863,929.34 | 66,929,219.47 | 38,183,215.47 | 141,319,719.97 |
| 研发费用 | 29,181,706.49 | 17,331,525.15 | 2,284,919.4 | 40,074,275.99 |
| 财务费用 | -16,651,883.99 | -10,631,179.37 | -6,195,873.66 | -9,584,138.59 |
| 其中:利息费用 | 1,788,712.36 | 979,507.5 | 44,140.83 | 2,001,956.99 |
| 其中:利息收入 | 7,712,636.19 | 4,936,232.11 | 2,845,406.13 | 8,729,753.29 |
| 加:公允价值变动收益 | 816,281.21 | 51,081.77 | -260,869.48 | -556,449.88 |
| 加:投资收益 | 1,476,489.13 | 4,075,054 | 1,507,311.86 | 8,612,757.89 |
| 资产处置收益 | 79,580.87 | 80,028.22 | - | -25,231.07 |
| 资产减值损失(新) | 1,552,679.83 | 1,488,891.34 | -252,039.34 | -67,290,056.12 |
| 信用减值损失(新) | -7,580,371.28 | 476,383.78 | 5,405,350.21 | -51,661,112.73 |
| 其他收益 | 2,977,073.61 | 1,780,436.65 | 996,748.41 | 8,139,125.1 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 11,014,699.56 | 13,473,832.44 | 14,693,107.21 | -121,223,467.99 |
| 加:营业外收入 | 10,077,979.72 | 10,006,400.69 | 7,621,779.22 | 2,939,562.36 |
| 减:营业外支出 | 537,576.14 | 215,179.37 | 24,788.73 | 9,360,918.41 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,555,103.14 | 23,265,053.76 | 22,290,097.7 | -127,644,824.04 |
| 减:所得税费用 | 1,960,864.39 | 4,592,078.07 | 3,933,784.11 | 33,178,991.43 |
| 六、净利润 | 18,594,238.75 | 18,672,975.69 | 18,356,313.59 | -160,823,815.47 |
| 持续经营净利润 | 18,594,238.75 | 18,672,975.69 | 18,356,313.59 | -160,823,815.47 |
| 归属于母公司股东的净利润 | 14,727,598.37 | 14,026,648.44 | 13,883,489.34 | -148,889,156.24 |
| 少数股东损益 | 3,866,640.38 | 4,646,327.25 | 4,472,824.25 | -11,934,659.23 |
| (一)基本每股收益 | 0.02 | 0.02 | 0.02 | -0.18 |
| (二)稀释每股收益 | 0.02 | 0.02 | 0.02 | -0.17 |
| 八、其他综合收益 | -2,006,874.66 | 1,838,850.17 | -823,337.38 | 967,814.67 |
| 归属于母公司股东的其他综合收益 | -4,584,700.94 | 1,767,440.55 | -568,264.94 | 526,764.08 |
| 九、综合收益总额 | 16,587,364.09 | 20,511,825.86 | 17,532,976.21 | -159,856,000.8 |
| 归属于母公司股东的综合收益总额 | 10,142,897.43 | 15,794,088.99 | 13,315,224.4 | -148,362,392.16 |
| 归属于少数股东的综合收益总额 | 6,444,466.66 | 4,717,736.87 | 4,217,751.81 | -11,493,608.64 |
| 公告日期 | 2024-10-29 | 2024-08-27 | 2024-04-30 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |